GAIN THERAPEUTICS, INC (GANX)

Every figure this model derived for GANX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 22,493 PaymentsToAcquireProductiveAssets 2024-12-31
cash 15,103,558 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 14,969,748 AssetsCurrent 2026-06-30
current liabilities 3,433,865 LiabilitiesCurrent 2026-06-30
equity 11,292,031 StockholdersEquity 2026-06-30
revenue 55,180 RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up GANX on one particular measure came for.

RatioValue
current ratio4.36
current ratio reported4.36
growth cv1.84
revenue growth-58.4
revenue growth per share-58.4
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about GANX's figures. Written by the derivation as it ran, not added afterwards.